Vascular dysfunction in human and rat cirrhosis: Role of receptor-desensitizing and calcium-sensitizing proteins

Hepatology

Volumn 45, Issue 2, 2007, Pages 495-506

  Hennenberg, Martin ^a   Trebicka, Jonel ^a   Biecker, Erwin ^a   Schepke, Michael ^a   Sauerbruch, Tilman ^a   Heller, Jörg ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN II; BETA ARRESTIN 2; CALCIUM; CALCIUM SENSITIZER; G PROTEIN COUPLED RECEPTOR KINASE 2; MOESIN; MYOSIN LIGHT CHAIN; PHOSPHATASE; PROTEIN A; RECEPTOR PROTEIN; RHO KINASE INHIBITOR; SEPHAROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BILE DUCT LIGATION; BLOOD VESSEL INJURY; CELL ISOLATION; CONTROLLED STUDY; DESENSITIZATION; ENZYME ACTIVITY; EXTRACELLULAR CALCIUM; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MUSCLE FIBER CONTRACTION; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; AORTA; ARRESTINS; BETA-ADRENERGIC RECEPTOR KINASE; CALCIUM; GTP-BINDING PROTEINS; HEPATIC ARTERY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; MALE; MICROFILAMENT PROTEINS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; VASOCONSTRICTION;

EID: 33847737104     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21502     Document Type: Article

References (47)

1. Heller J, Schepke M, Gehnen N, Molderings G, Müller A, Erhard J, et al. Altered adrenergic responsiveness of endothelium denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999;116:387-393.
2. Schepke M, Heller J, Paschke S, Thomas J, Wolff M, Neef M, et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. HEPATOLOGY 2001;34:884-888.
3. Hadoke PW, Hayes PC. In vitro evidence for vascular hyporesponsiveness in clinical and experimental cirrhosis. Pharmacol Ther 1997;75:51-68.
4. Hadoke PW. Cirrhosis of the liver and receptor-mediated function in vascular smooth muscle. Pharmacol Ther 2001;89:233-54.
5. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophyiology and clinical consequences. HEPATOLOGY 1994;20:1359-1363.
6. Vorobioff J, Bredfeldt J, Groszmann R. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G57.
7. Shah V. Cellular and molecular basis of portal hypertension. Clin Liv Dis 2001;5:629-644.
8. Langer DA, Shah VJ. Nitric oxide and portal hypertension: Interface of vasoreactivity and angiogenesis. J Hepatol 2006;44:209-216.
9. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002;35:478-491.
10. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074-G1081.
11. Michielsen PP, Boeckxstaens GE, Sys SU, Herman AG, Pelckmans PA. The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. J Hepatol 1995;23:341-347.
12. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-854.
13. Colle IO, De Vriese AS, Van Vlierberghe HR, Lameire NH, De Vos MM. Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroent Hep 2004;16:139-145.
14. Somlyo AP, Wu X, Walker LA, Somlyo AV. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol 1999;134:201-234.
15. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and non-muscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358.
16. Kanaide H, Ichiki T, Nishimura J, Hirano K. Cellular mechanism of vasoconstriction induced by angiotensin II. Circ Res 2003;93:1015-1017.
17. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002;115:455-465.
18. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003;375:503-515.
19. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53:1-24.
20. Thomas WG, Qian H. Arresting angiotensin type 1 receptors. Trends Endocrin Metabol 2003;14:130-136.
21. Böhm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997;322:1-18.
22. Bünemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 1999;517:5-23.
23. Willets JM, Challiss RAJ, Nahorski SR. Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci 2003;24:626-633.
24. 2+- sensitization in rabbit smooth muscle. J Physiol 2003;546:879-889.
25. Bolz SS, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 2003;107:3081-3087.
26. Mitsui T, Kitazawa T, Ikebe M. Correlation between high temperature dependence of smooth muscle myosin light chain phosphatase activity and muscle relaxation rate. J Biol Chem 1994;269:5842-5848.
27. Pyne GJ, Cadoux-Hudson TAD, Clark JF. The presence of an extractable substance in the CSF of humans with cerebral vasospasm after subarachnoid haemorrhage that correlates with phosphatase inhibition. Biochim Biophys Acta 2000;1474:283-290.
28. Neef M, Biecker E, Heller J, Schepke M, Nischalke HD, Wolff M, et al. Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. Eur J Clin Invest 2003;33:249-255.
29. Gaudin C, Launay JM, Moreau R, Cailmail S, Lebrec D. Discrepant regulation among alpha and beta adrenoceptors in vascular walls of cirrhotic rats [Abstract]. J Hepatol 1994;21:S43.
30. Stoll M, Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 2001;99:175-182.
31. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 1999;17:1775-1786.
32. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005;14:67-71.
33. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003;12:70-88.
34. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides 2005;26:1401-1409.
35. Gross V, Obst M, Luft FC. Insights into angiotensin II receptor function through AT2 receptor knockout mice. Acta Physiol Scand 2004;181:487-494.
36. Barnes WG, Reiter E, Violin JD, Ren XR, Milligen G, Lefkowitz RJ. Beta-arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem 2005;280:8041-8050.
37. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005;11:952-958.
38. Payne MC, Zhang HY, Shirasawa Y, Koga Y, Ikebe M, Benoit JN, et al. Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. Am J Phyiol Heart Circ Physiol 2004;286:H1801-H1810.
39. Shenoy SK, Lefkowitz. Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE 2005;2005(308):cm10.
40. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A 2005;102:1442-1447.
41. McDonald PH, Lefkowitz RJ. βArrestins: new roles in regulating heptahelical receptors' functions. Cell Signal 2001;13:683-689.
42. Miller WE, Lefkowitz RJ. Expanding roles for β-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Op Cell Biol 2001;13:139-145.
43. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science 2005;308:512-517.
44. Shenoy SK, Lefkowitz. Angiotensin II-stimulated signaling through G proteins and beta-arrestin. Sci STKE 2005;2005(311):cm14.
45. Pawlak G, Helfman DM. Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. Mol Biol Cell 2002;13:336-347.
46. Zhang HY, Shirasawa Y, Chen X, Yu H, Benoit JN. Impaired agonist-dependent myosin phosphorylation and decreased RhoA in rat portal hypertensive mesenteric vasculature. Am J Physiol Gastrointest Liver Physiol 2005;288:G603-G608.
47. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305.